Tissue polypeptide specific antigen (TPS) assay, TPS is a kind of sugar-free protein widely distributed in normal tissue cells of the body, but the content is extremely low, when the cells are in the proliferation and division phase, its content is elevated, and the malignant tumor cells are abnormally active in proliferation, the cells produce and secrete a large amount of TPS, and the patients’ serum TPS concentration is obviously elevated, so TPS can be used as a markers of malignant tumors. It is especially suitable for the screening of breast and ovarian malignant tumors. Studies at home and abroad have shown that TPS can be used as a novel marker for breast cancer. In breast cancer patients, TPS is expressed at a high level, and their serum TPS concentration value is significantly elevated, which can reach more than 150 U/L. Among breast cancer patients with distant metastasis, about 87% of them will have significantly elevated serum TPS, while only 64% of them will have elevated CA153. In recurrent breast cancer patients, TPS rises earlier than CA153, and the degree of increase is more obvious.TPS can detect tumor metastasis 6.8 months earlier, and some studies have concluded that the median survival time of patients with low levels of TPS is 815 days, and the median survival time of patients with high levels of TPS is 332 days. Therefore, serum TPS level detection provides an early and effective screening means for benign and malignant identification of breast tumors, and provides an effective serum monitoring means during gynecologic tumor treatment. In addition, some scholars found that TPS>120 U/L can be used as a high-risk factor indicator for ovarian cancer. In ovarian cancer patients with distant metastasis, 97% of them had significantly elevated TPS concentration, while only 81% had elevated CA125. TPS combined with CAl25 has significant significance in determining the prognosis of ovarian cancer patients after chemotherapy.